Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Streptococcus pneumoniae Capsular Polysaccharides.

Pavliakova D, Giardina PC, Moghazeh S, Sebastian S, Koster M, Pavliak V, McKeen A, French R, Jansen KU, Pride M.

mSphere. 2018 Aug 8;3(4). pii: e00128-18. doi: 10.1128/mSphere.00128-18.

2.

Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides.

Tan CY, Immermann FW, Sebastian S, Pride MW, Pavliakova D, Belanger KA, Watson W, Scott DA, Sidhu M, Jansen KU, Giardina PC.

mSphere. 2018 Aug 8;3(4). pii: e00127-18. doi: 10.1128/mSphere.00127-18.

3.

Assignment of Weight-Based Antibody Units for Four Additional Serotypes to a Human Antipneumococcal Standard Reference Serum, 007sp.

Goldblatt D, McKeen A, Burbidge P, McElhiney S, McLaughlin L, Johnson A, Rauh M, Giardina PC.

Clin Vaccine Immunol. 2017 Sep 5;24(9). pii: e00194-17. doi: 10.1128/CVI.00194-17. Print 2017 Sep.

4.

A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations.

Wysocki J, Center KJ, Brzostek J, Majda-Stanislawska E, Szymanski H, Szenborn L, Czajka H, Hasiec B, Dziduch J, Jackowska T, Witor A, Kopińska E, Konior R, Giardina PC, Sundaraiyer V, Patterson S, Gruber WC, Scott DA, Gurtman A.

Vaccine. 2017 Apr 4;35(15):1926-1935. doi: 10.1016/j.vaccine.2017.02.035. Epub 2017 Mar 3.

5.

Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants.

Martinón-Torres F, Wysocki J, Center KJ, Czajka H, Majda-Stanislawska E, Omeñaca F, Concheiro-Guisan A, Gimenez-Sanchez F, Szenborn L, Blázquez-Gamero D, Moreno-Galarraga L, Giardina PC, Sun G, Gruber WC, Scott DA, Gurtman A.

Pediatr Infect Dis J. 2017 Mar;36(3):326-332. doi: 10.1097/INF.0000000000001428.

PMID:
27902652
6.

Long-term antibody persistence study (3 years after last dose) of the 7-valent pneumococcal conjugate vaccine in young children in China.

Li R, Fang KX, Young M Jr, Zhou X, Chen Z, Liang JZ, Giardina PC, Scott DA.

Vaccine. 2016 Oct 17;34(44):5359-5365. doi: 10.1016/j.vaccine.2016.08.070. Epub 2016 Sep 8.

7.

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China.

Zhu F, Hu Y, Li J, Ye Q, Young MM Jr, Zhou X, Chen Z, Yan B, Liang JZ, Gruber WC, Giardina PC, Scott DA.

Pediatr Infect Dis J. 2016 Sep;35(9):999-1010. doi: 10.1097/INF.0000000000001248.

PMID:
27254028
8.

Assignment of Weight-Based Antibody Units for Seven Additional Serotypes to a Human Pneumococcal Standard Reference Serum, 007sp.

Goldblatt D, Tan CY, Burbidge P, McElhiney S, McLaughlin L, Tucker R, Rauh M, Sidhu M, Giardina PC.

Clin Vaccine Immunol. 2015 Nov;22(11):1154-9. doi: 10.1128/CVI.00437-15. Epub 2015 Sep 9.

9.

Safety, tolerability, and immunogenicity of 7-valent pneumococcal conjugate vaccine in older infants and young children in China who are naive to pneumococcal vaccination: Results of a phase 4 open-label trial.

Li R, Huang L, Mo S, Li J, Zhou X, Chen Z, Liang J, Young M Jr, Giardina PC, Scott DA.

Vaccine. 2015 Jul 9;33(30):3580-5. doi: 10.1016/j.vaccine.2015.05.042. Epub 2015 Jun 1.

10.

Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.

Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V, Giardina PC, Clarke K, Gruber WC, Scott DA, Schmoele-Thoma B; 3003 Study Group.

Clin Infect Dis. 2015 Aug 1;61(3):313-23. doi: 10.1093/cid/civ287. Epub 2015 Apr 13.

11.

13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants.

Martinón-Torres F, Czajka H, Center KJ, Wysocki J, Majda-Stanislawska E, Omeñaca F, Bernaola Iturbe E, Blazquez Gamero D, Concheiro-Guisán A, Gimenez-Sanchez F, Szenborn L, Giardina PC, Patterson S, Gruber WC, Scott DA, Gurtman A.

Pediatrics. 2015 Apr;135(4):e876-86. doi: 10.1542/peds.2014-2941. Epub 2015 Mar 16.

12.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.

Wysocki J, Brzostek J, Szymański H, Tetiurka B, Toporowska-Kowalska E, Wasowska-Królikowska K, Sarkozy DA, Giardina PC, Gruber WC, Emini EA, Scott DA.

Vaccine. 2015 Mar 30;33(14):1719-25. doi: 10.1016/j.vaccine.2015.02.005. Epub 2015 Feb 17.

PMID:
25698485
13.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 given to healthy infants at 2, 3, 4 and 12 months of age.

Gadzinowski J, Tansey SP, Wysocki J, Kopińska E, Majda-Stanisławska E, Czajka H, Korbal P, Pietrzyk JJ, Baker SA, Giardina PC, Gruber WC, Emini EA, Scott DA.

Pediatr Infect Dis J. 2015 Feb;34(2):180-5. doi: 10.1097/INF.0000000000000511.

PMID:
25126854
14.

Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.

Diez-Domingo J, Gurtman A, Bernaola E, Gimenez-Sanchez F, Martinon-Torres F, Pineda-Solas V, Delgado A, Infante-Marquez P, Liang JZ, Giardina PC, Gruber WC, Emini EA, Scott DA.

Vaccine. 2013 Nov 4;31(46):5486-94. doi: 10.1016/j.vaccine.2013.06.049. Epub 2013 Sep 1.

PMID:
24004465
15.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico.

Gutiérrez Brito M, Thompson A, Girgenti D, Giardina PC, Sarkozy DA, Gruber WC, Emini EA, Scott DA.

Rev Panam Salud Publica. 2013 Jun;33(6):414-21.

PMID:
23939366
16.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.

Togashi T, Yamaji M, Thompson A, Giardina PC, Aizawa M, Patterson S, Gruber WC, Scott DA; 3003 Study Group.

Pediatr Infect Dis J. 2013 Sep;32(9):984-9. doi: 10.1097/INF.0b013e318293007e.

PMID:
23538524
17.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.

Kim DS, Shin SH, Lee HJ, Hong YJ, Lee SY, Choi KM, Oh CE, Kim KH, Juergens C, Patterson S, Giardina PC, Gruber WC, Emini EA, Scott DA.

Pediatr Infect Dis J. 2013 Mar;32(3):266-73. doi: 10.1097/INF.0b013e3182748bb6.

PMID:
23011012
18.

A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults.

Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL.

Hum Vaccin Immunother. 2012 Jul;8(7):888-95. doi: 10.4161/hv.19983. Epub 2012 Jul 1.

PMID:
22832260
19.

Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.

Frenck RW Jr, Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D, Giardina PC, Emini EA, Gruber WC, Scott DA, Schmöle-Thoma B.

Clin Vaccine Immunol. 2012 Aug;19(8):1296-303. doi: 10.1128/CVI.00176-12. Epub 2012 Jun 27.

20.

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage.

Ala'aldeen DA, Flint M, Oldfield NJ, Omer SA, McNeil LK, Jiang Q, Murphy E, Giardina PC, Novikova EG, Dodge-Scully IL, Bayliss CD, Turner DP, Neal KR, Hoiseth SK, Jansen KU, Anderson AS.

Vaccine. 2010 Nov 10;28(48):7667-75. doi: 10.1016/j.vaccine.2010.09.038. Epub 2010 Sep 25.

PMID:
20875489
21.

Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide.

Giardina PC, Longworth E, Evans-Johnson RE, Bessette ML, Zhang H, Borrow R, Madore D, Fernsten P.

Clin Diagn Lab Immunol. 2005 May;12(5):586-92.

23.

Isolation and analysis of radiolabeled meningococcal endotoxin.

Giardina PC, Weiss JA, Gibson BW, Apicella MA.

Methods Mol Med. 2001;67:441-58. doi: 10.1385/1-59259-149-3:441.

PMID:
21337160
24.

Construction of acetate auxotrophs of Neisseria meningitidis to study host-meningococcal endotoxin interactions.

Giardina PC, Gioannini T, Buscher BA, Zaleski A, Zheng DS, Stoll L, Teghanemt A, Apicella MA, Weiss J.

J Biol Chem. 2001 Feb 23;276(8):5883-91. Epub 2000 Nov 17.

25.

Interaction of the gonococcal porin P.IB with G- and F-actin.

Wen KK, Giardina PC, Blake MS, Edwards J, Apicella MA, Rubenstein PA.

Biochemistry. 2000 Jul 25;39(29):8638-47.

PMID:
10913272
26.

Macropinocytosis as a mechanism of entry into primary human urethral epithelial cells by Neisseria gonorrhoeae.

Zenni MK, Giardina PC, Harvey HA, Shao J, Ketterer MR, Lubaroff DM, Williams RD, Apicella MA.

Infect Immun. 2000 Mar;68(3):1696-9.

27.

Neisseria gonorrhoeae induces focal polymerization of actin in primary human urethral epithelium.

Giardina PC, Williams R, Lubaroff D, Apicella MA.

Infect Immun. 1998 Jul;66(7):3416-9.

28.

Analysis of the alcABC operon encoding alcaligin biosynthesis enzymes in Bordetella bronchiseptica.

Giardina PC, Foster LA, Toth SI, Roe BA, Dyer DW.

Gene. 1997 Jul 18;194(1):19-24.

PMID:
9266668
29.

Identification of alcA, a Bordetella bronchiseptica gene necessary for alcaligin production.

Giardina PC, Foster LA, Toth SI, Roe BA, Dyer DW.

Gene. 1995 Dec 29;167(1-2):133-6.

PMID:
8566764
30.

bvg Repression of alcaligin synthesis in Bordetella bronchiseptica is associated with phylogenetic lineage.

Giardina PC, Foster LA, Musser JM, Akerley BJ, Miller JF, Dyer DW.

J Bacteriol. 1995 Nov;177(21):6058-63.

31.

Peptide mimicry of the meningococcal group C capsular polysaccharide.

Westerink MA, Giardina PC, Apicella MA, Kieber-Emmons T.

Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4021-5.

32.

Anti-idiotype induced protection against Neisseria meningitidis serogroup C bacteremia.

Westerink MA, Giardina PC.

Microb Pathog. 1992 Jan;12(1):19-26.

PMID:
1560751
33.

Supplemental Content

Loading ...
Support Center